Tag Archives: health

Hot Investor Mandate: Venture Arm of Large Drug Development Organization Supports Drug Discovery Companies With Seed and Later-Stage Investments 

2 Jun

A corporate venture capital investor headquartered in Asia is an investment arm of a large drug development organization. The firm invests globally across all stages, from Seed through later-stage financings. In addition to providing capital, the firm offers strategic and operational support spanning drug development, regulatory planning, partnering, and commercialization. The firm leverages the broader capabilities and infrastructure of its affiliated organization to help portfolio companies accelerate growth and value creation.  
 
The firm focuses on pharmaceuticals, biotechnology, and medical devices, with a strong emphasis on drug discovery and translational innovation. The firm seeks differentiated therapeutic and medical technology opportunities with strong scientific foundations and commercial potential. Within therapeutics, the firm is modality-agnostic and evaluates opportunities across a broad range of disease areas and development stages, from discovery through clinical development. The firm also participates in licensing, incubation, and strategic business development activities designed to advance promising healthcare technologies.  
 
From a company and management team perspective, the firm seeks founders and leadership teams with strong scientific expertise, differentiated intellectual property, and credible development strategies. The firm prioritizes opportunities supported by high-quality translational science and works closely with management teams to provide development resources, business development support, partnering opportunities, and commercialization expertise. Through its strategic network and operational capabilities, the firm helps portfolio companies accelerate development timelines and expand global market access. 

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com. 

Tags: , , , , ,

Hot Investor Mandate: Multi-Stage Healthcare Investment Firm Seeks Early Clinical Stage Therapeutics and Devices Near Regulatory Approval, Investing Up to $20M

2 Jun

A capital and private equity investor with a flexible investment mandate invests across a wide range of stages and sectors. On the venture capital side, the firm typically participates in Seed through Series B financings and is open to both leading and co-investing. Investments are generally made through special purpose vehicles, with typical allocation sizes ranging from approximately $2M to $20M. The firm primarily focuses on opportunities within the United States.  

Within healthcare and life sciences, the firm invests in therapeutics, medical devices, digital health, and diagnostics. For therapeutics, the firm prefers opportunities that are approaching clinical development or already in clinical trials. Within medical devices, the firm focuses on technologies that are nearing regulatory approval or have already obtained clearance or approval. The firm is disease-agnostic and evaluates opportunities based on the strength of the technology, clinical potential, and commercial opportunity.  

From a company and management team perspective, the firm generally prefers board representation and seeks to work closely with portfolio companies to support strategic growth and value creation. 

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com. 

Tags: , , , , ,

Hot Investor Mandate: USA-Based VC Firm Focuses on Deeptech and Techbio Investments in Pre-Seed to Series A Rounds

2 Jun

A venture capital firm headquartered in the United States focuses on Pre-Seed through Series A opportunities across deeptech, life sciences, and the convergence of technology and healthcare. Backed by family offices and strategic investors across multiple regions, the firm benefits from a network of partners with entrepreneurial and life sciences expertise. The firm typically participates as a co-investor with check sizes ranging from approximately $100K to $1M. In addition to venture investing, the firm collaborates with capital partners on strategic acquisition opportunities and actively supports company formation and incubation. The firm invests globally and assists portfolio companies with expansion into emerging markets across Asia, Africa, and other regions. 

The firm takes an opportunistic approach to life sciences and deeptech investing. Key areas of interest include artificial intelligence, health technology, neuroscience, life science tools, and therapeutics. The firm is also open to orphan disease opportunities. Within therapeutics, the firm focuses on companies from the preclinical stage through Phase I clinical development. The firm seeks differentiated technologies with the potential to create meaningful scientific, clinical, or commercial impact. 

From a company and management team perspective, the firm does not impose specific requirements regarding leadership composition and does not require board representation as a condition of investment. The firm prefers to support founders through collaborative partnerships and strategic guidance while maintaining flexibility in investment structure and governance. 

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com. 

Tags: , , , , ,

Hot Investor Mandate: CVC Arm of Leading Healthcare Company Allocates Up to $10M in Growth-Stage Therapeutics and Diagnostics Companies

2 Jun

The firm is a corporate venture capital arm of a leading healthcare and diagnostics company based in Asia. The firm focuses on investing in later-stage life sciences and healthcare companies, typically from growth-stage financings through post-IPO opportunities. The firm generally makes investments below $10M per company and maintains a selective investment strategy. The firm evaluates opportunities globally and leverages the expertise, industry relationships, and commercial infrastructure of its parent organization to support portfolio companies.  

The firm primarily focuses on therapeutics and diagnostics, while remaining open to select medical device and digital health opportunities. Within therapeutics, the firm is most interested in programs ranging from mid- to late-stage clinical development through commercial-stage assets. Areas of interest include cardiovascular diseases, respiratory diseases, oncology, autoimmune disorders, urology, and central nervous system disorders. Within in vitro diagnostics, the firm is open to a broad range of technologies spanning development-stage through clinical and commercial applications.  

From a company and management team perspective, the firm seeks technologies with strong scientific foundations, clear commercial potential, and a high likelihood of successfully navigating regulatory approval pathways. As a strategic investor, the firm prioritizes opportunities that demonstrate meaningful differentiation and long-term market potential. 

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com. 

Tags: , , , , ,

Investors Presenting at RESI San Diego

2 Jun

By Claire Jeong, Chief Conference Officer, Vice President of Investor Research, Asia BD, LSN

The Life Science Nation (LSN) team is gearing up for the highly anticipated RESI San Diego conference, bringing together investors, strategic partners, and early-stage life science innovators for a full day of insightful discussions and high-value networking during Convention Week.

This year’s panel lineup will explore some of the most important trends shaping early-stage healthcare investment and partnering, spanning pharma, medtech, diagnostics, oncology, AI, and venture financing. Attendees can expect perspectives from venture capital firms, corporate venture groups, pharmaceutical companies, strategics, and experienced healthcare investors actively evaluating emerging opportunities across the life science landscape.

As a global partnering conference focused on connecting early-stage companies with investors and strategic partners, RESI San Diego is designed to foster meaningful conversations between fundraising CEOs and active dealmakers. The panels will provide tactical insight into how investors assess opportunities, what strategic partners are looking for, and how companies can position themselves in today’s increasingly competitive fundraising environment.

Join the panelists below at RESI San Diego:

Friedemann-Janus
Friedemann Janus
Bayer		 Shiv-Krishnan
Shiv Krishnan
Daiichi Sankyo Co., Ltd.		 Eva-Dahlen
Eva Dahlén
Novo Nordisk
Yaron-Daniely
Yaron Daniely
aMoon Fund		 Claudia-Generaux
Claudia Generaux
Bristol Myers Squibb		 Lana Ghanem
Lana Ghanem
Hikma Ventures
Kit-Law
Mankit Law
GlaxoSmithKline (GSK)		 Debbie-Lin
Debbie Lin
T.Rx Capital		 Priya-Balachandran
Priya Balachandran
Life Science Angels
Andrew-Strong
Andrew Strong
Cancer Focus Fund		 Randy-Berholtz
Randy Berholtz
Mesa Verde Venture Partners		 Gunes-Bozkurt
Gunes Bozkurt
Beiersdorf
Damian-Carvajal-Ibanez
Damian Carvajal Ibanez
Debiopharm		 Nicolas-Cindric
Nicolas Cindric
Yahara Ventures		 Han-Dai
Han Dai
Viva BioInnovator
Luca-Giani
Luca Giani
Alumni Ventures		 Sam-Gussman-Toh
Sam Gussman-Toh
ARPA-H		 Ole-Henrik-Bang-Andreasen
Ole Henrik Bang Andreasen
Avant Bio
Rohit-Jain
Rohit Jain
HBS Alumni Angels of Northern California		 Ray-Jordan
Ray Jordan
Elmstead Holdings		 Mohsin-Khan
Mohsin Khan
Fortress Biotech
Cheryl-Kuai
Cheryl Kuai
Sixty Degree Capital		 Don-Lin
Don Lin
Guoqian Venture Capital Investment		 Andrew-Merken
Andrew Merken
Polsinelli PC
Ralph-Morales
Ralph Morales III
Aquillius Ventures		 Nick-Mourlas
Nick Mourlas
ReefHaven Ventures		 Mahesh-Narayanan
Mahesh Narayanan
Neuvation Ventures
Stephanie-Oestreich
Stephanie Oestreich
Myeloma Investment Fund		 Soyoung-Park
Soyoung Park
1004 Venture Partners		 Preetha-Ram
Preetha Ram
Pier 70 Ventures
Bob-Sweeney
Bob Sweeney
Global Health Impact Fund		 Divya-Yerraguntla
Divya Yerraguntla
Life Science Angels		 Chris-Yoo
Chris Yoo
Xcellerant Ventures
Register for RESI San Diego

Tags: , , , , , , , , , , , , ,

INNOPOLIS Jeonbuk, Title Sponsor of RESI San Diego 2026, to Host Jeonbuk Advanced Bio Boost-Up Innovation Showcase

27 May

By Claire Jeong, Chief Conference Officer, Vice President of Investor Research, Asia BD, LSN

Life Science Nation (LSN) is pleased to announce the INNOPOLIS Jeonbuk as a Title Sponsor of RESI San Diego 2026.

As part of the Jeonbuk Advanced Bio Boost-Up Platform initiative, INNOPOLIS Jeonbuk will host the Jeonbuk Advanced Bio Boost-Up Innovation Showcase at RESI San Diego on Monday, June 22, 10:00am – 12:00pm, featuring innovative life science companies from South Korea. The showcase aims to highlight emerging Korean biotech and healthcare technologies while connecting participating companies with global investors, strategic partners, and commercialization opportunities.

The Jeonbuk Advanced Bio Boost-Up Platform initiative is supported by the Ministry of Science and ICT of Korea and the Korea Innovation Foundation (INNOPOLIS Foundation), with the goal of strengthening Jeonbuk’s position as a global bio innovation hub. Through this initiative, regional startups and emerging companies are being supported in their efforts to expand internationally and engage with the global life science ecosystem.

South Korea has rapidly emerged as one of Asia’s leading biotechnology and healthcare markets, supported by strong scientific talent, advanced manufacturing capabilities, and increasing government investment in innovation. Within this landscape, Jeonbuk is actively developing its bio industry through strategic support for therapeutics, medical devices, digital health, diagnostics, regenerative medicine, and advanced biomanufacturing.

Participating companies include:

WittGen Biotechnologies – developer of a GenAI-based single-cell multi-omics simulation platform focused on oncology, immunology, and rare diseases.

 

Cellebrain – advancing MSC-based gene delivery technologies for oncology, fibrosis, and rare disease applications.

 

Youth Bio Global – developing allogeneic ECFC-based regenerative cell therapy platforms targeting vascular regeneration and ischemic diseases.

 

Erudio Bio Korea – developer of semiconductor-based multiplex diagnostic and AI molecular analysis technologies for preventive screening and oncology applications.

 

BASGENBIO Co., Ltd. – an AI-driven drug discovery company focused on target discovery and preclinical decision-support technologies.

 

VIEL-T Co., Ltd. – developing programmable RNA therapeutics platforms for next-generation precision medicine applications.

In connection with the initiative, INNOPOLIS Jeonbuk recently hosted the Global Investment Attraction Strategy & IR Capability Enhancement Seminar on May 21, 2026, at the Jeonbuk Techno Business Center in South Korea. The seminar brought together regional biotech companies, ecosystem stakeholders, and industry experts to discuss global fundraising strategies, investor engagement, and international commercialization opportunities for Korean life science companies.

As part of the program, Life Science Nation (LSN) shared insights on:

  • Global fundraising and investor outreach strategies
  • Building effective IR and partnering pipelines
  • Preparing Korean startups for international investors and markets
  • Opportunities through RESI and the global LSN ecosystem

The event also included the signing of a Memorandum of Understanding (MOU) between LSN and BSR Korea to strengthen collaboration in supporting Korean biotech and healthcare companies seeking global expansion and cross-border partnership opportunities.

Through the showcase at RESI San Diego 2026, INNOPOLIS Jeonbuk seeks to strengthen cross-border collaboration and provide Korean startups with greater access to global capital and partnering opportunities.

The program will feature:

  • An introduction to the Jeonbuk bio ecosystem and the Jeonbuk Advanced Bio Boost-Up Platform initiative
  • Startup pitches from participating Korean life science companies
  • Investor and industry expert feedback sessions
  • Networking opportunities with global investors and strategic partners

RESI San Diego 2026 will take place on Monday, June 22, at the JULEP Venue in San Diego. Join us for a full day of one-on-one partnering meetings, engaging programming, and the opportunity to build meaningful connections within the global life sciences ecosystem.

About INNOPOLIS Jeonbuk

The INNOPOLIS Jeonbuk is part of Korea’s national innovation cluster network operated by the Korea Innovation Foundation under the Ministry of Science and ICT. Based in Jeonbuk Special Self-Governing Province, the cluster supports the commercialization and global expansion of innovative technologies and startups across the life sciences sector.

Through the Jeonbuk Advanced Bio Boost-Up Platform initiative, the cluster is focused on strengthening regional bio innovation capabilities and supporting Korean life science companies in accessing global investors, strategic partners, and international markets.

As a Title Sponsor of RESI San Diego 2026, the INNOPOLIS Jeonbuk aims to expand global collaboration opportunities for Korean startups and further connect the Korean bio ecosystem with the international life science community.

Register for RESI San Diego

Tags: , , , , , , , , , , , , ,

New Frontiers in Diagnostics: Investors Look Toward Earlier Detection and Smarter Disease Monitoring at RESI San Diego 

27 May

By Momo Yamamoto, Senior Investor Research Analyst, LSN

At RESI San Diego, the “New Frontiers in Diagnostics: Investing in Technologies Enabling Earlier Disease Detection” panel will bring together investors and industry leaders to explore one of the most rapidly evolving areas in healthcare innovation: diagnostics.

As advances in liquid biopsies, molecular diagnostics, AI-enabled imaging, and point-of-care technologies continue to reshape healthcare, diagnostics are increasingly moving beyond simple detection tools and becoming central to disease prevention, monitoring, and personalized treatment strategies. Earlier and more precise detection has the potential to improve patient outcomes, reduce healthcare costs, and create entirely new models of care delivery.

Meet the Panelists

Priya-Balachandran
Priya Balachandran
Life Science Angels
(Moderator)		 Randy-Berholtz
Randy Berholtz
Mesa Verde Venture Partners		 Yaron-Daniely
Yaron Daniely
aMoon Fund
Debbie-Lin
Debbie Lin
T.Rx Capital		 Soyoung-Park
Soyoung Park
1004 Venture Partners

The panel will examine where investors and strategic partners see the greatest opportunities emerging across the diagnostics landscape, particularly in oncology screening, cardiometabolic disease, and chronic disease monitoring. With healthcare systems placing greater emphasis on prevention and longitudinal patient management, diagnostic companies are facing growing demand—but also increasing pressure to demonstrate meaningful clinical and economic value.

For early-stage companies, the diagnostics space presents unique opportunities alongside complex commercialization challenges. Unlike many therapeutics companies, diagnostics startups must often navigate overlapping clinical validation, reimbursement, regulatory, and adoption hurdles simultaneously. Investors are increasingly looking for companies that can clearly demonstrate clinical utility, integrate effectively into provider workflows, and build compelling reimbursement strategies early in development.

Panelists are expected to discuss the milestones and study designs that help diagnostic companies stand out in a crowded and competitive market. Topics may include generating real-world evidence, designing validation studies that resonate with payers and providers, and establishing partnerships with laboratories, health systems, and pharmaceutical companies to accelerate adoption.

The rise of AI-enabled diagnostics is also expected to play a central role in the conversation. As machine learning tools become more integrated into imaging, pathology, and predictive analytics platforms, investors are paying close attention to how startups validate algorithms, manage regulatory considerations, and demonstrate measurable improvements in clinical decision-making.

Beyond the technology itself, the panel will likely explore broader market trends shaping investor interest in diagnostics. Healthcare systems worldwide continue shifting toward preventative care models, while aging populations and rising chronic disease burdens increase demand for scalable monitoring solutions. In this environment, diagnostics companies capable of delivering actionable insights earlier in the patient journey may be particularly well-positioned to attract strategic partnerships and investment.

For founders attending RESI San Diego, the session offers an opportunity to better understand how investors evaluate diagnostics opportunities in today’s market and what differentiates successful companies from the broader field. From regulatory and reimbursement strategy to commercialization planning and partnership development, the panel aims to provide practical insight into building investable diagnostic platforms in an increasingly competitive healthcare landscape.

The “New Frontiers in Diagnostics” panel is part of RESI San Diego’s broader programming focused on emerging healthcare technologies, investment trends, and strategies for early-stage companies navigating today’s life science funding environment.

Register for RESI San Diego

Tags: , , , , , , , , , , , , , , , ,

← Older Entries
Newer Entries →